These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 486308)

  • 1. ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
    Kovacs CJ; Evans MJ; Burholt DR; Schenken LL
    Br J Cancer; 1979 May; 39(5):524-30. PubMed ID: 486308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
    Kovacs CJ; Evans MJ; Schenken LL; Burholt DR
    Br J Cancer; 1979 May; 39(5):516-23. PubMed ID: 486307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potentiation of combined cis-dichlorodiammineplatinum (II) and irradiation by ICRF-159.
    Kovacs CJ; Schenken LL; Burholt DR
    Int J Radiat Oncol Biol Phys; 1979 Aug; 5(8):1361-4. PubMed ID: 575120
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of radiation and razoxane (ICRF 159) in vivo.
    Hellmann K; Grimshaw MB; Hutchinson GE
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
    [No Abstract]   [Full Text] [Related]  

  • 5. Maximizing therapeutic gain with gemcitabine and fractionated radiation.
    Mason KA; Milas L; Hunter NR; Elshaikh M; Buchmiller L; Kishi K; Hittelman K; Ang KK
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1125-35. PubMed ID: 10421547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
    Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
    Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.
    Taylor IW; Bleehen NM
    Br J Cancer; 1977 May; 35(5):587-94. PubMed ID: 861147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of a mouse sarcoma using razoxane and electron irradiation.
    Grimshaw MB; Davies RW; Hall WS
    Br J Cancer; 1981 Jul; 44(1):117-23. PubMed ID: 7259958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
    Zwilling BS; Campolito LB; Reiches NA; George T; Witiak DT
    Br J Cancer; 1981 Oct; 44(4):578-83. PubMed ID: 7295515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro.
    Taylor IW; Bleehen NM
    Br J Cancer; 1977 Oct; 36(4):493-500. PubMed ID: 588416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.
    Wheeler RH; Clauw DJ; Natale RB; Ruddon RW
    Invest New Drugs; 1983; 1(4):283-95. PubMed ID: 6432722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
    Dyment PG; Starling KA; Land VJ; Cangir A; Komp DM; Sexauer CL
    Cancer Treat Rep; 1979 Aug; 63(8):1397-8. PubMed ID: 476712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic activity of ICRF-159 combined with surgery: effects of postsurgical treatment with cyclophosphamide in mice bearing Lewis lung carcinoma lines.
    Sava G; Zorzet S; Perissin L
    Anticancer Res; 1985; 5(5):511-5. PubMed ID: 4062252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187.
    El-Hage AN; Herman EH; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):509-23. PubMed ID: 7036302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of AT1727 on growth and metastasis of murine tumours.
    Li XT; Hutchinson GE; Pym BA; Finch M; Hellmann K
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):283-7. PubMed ID: 6681774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 17. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
    Liesmann J; Belt R; Haas C; Hoogstraten B
    Cancer; 1981 Apr; 47(8):1959-62. PubMed ID: 6784914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine intestinal crypt survival after combined taxol plus radiation exposure.
    Lojun SL; Sigdestad CP; Connor AM; Spanos WJ; Bosscher JR
    Gynecol Oncol; 1996 Nov; 63(2):180-3. PubMed ID: 8910624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.